Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition

References

• Panizo S, Martínez-Arias L, Alonso-Montes C, et al. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci. 2021;22(1):1. doi:10.3390/ijms22010408.
   Web of Science ®Google Scholar
• Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15(3):144–14. doi:10.1038/s41581-019-0110-2.
   PubMed Web of Science ®Google Scholar
• Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15(1):123–147. doi:10.1146/annurev-pathmechdis-012418-012718.
   PubMed Web of Science ®Google Scholar
• Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci. 2008;13(13):453–461. doi:10.2741/2692.
   PubMed Web of Science ®Google Scholar
• Liu YC, Zou XB, Chai YF, et al. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014;10(5):520–529. doi:10.7150/ijbs.8879.
   PubMed Web of Science ®Google Scholar
• Chen T, Cao Q, Wang Y, et al. M2 macrophages in kidney disease: biology, therapies, and perspectives. Kidney Int. 2019;95(4):760–773. doi:10.1016/j.kint.2018.10.041.
   PubMed Web of Science ®Google Scholar
• Braga TT, Agudelo JS, Camara NO. Macrophages during the fibrotic process: m 2 as friend and foe. Front Immunol. 2015;6:602. doi:10.3389/fimmu.2015.00602.
   PubMed Web of Science ®Google Scholar
• Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis, the. J Clin Invest. 2002;110(3):341–350. doi:10.1172/JCI0215518.
   PubMed Web of Science ®Google Scholar
• Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19(12):2282–2287. doi:10.1681/ASN.2008050513.
   PubMed Web of Science ®Google Scholar
• Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol. 2012;27(2):183–193. doi:10.1007/s00467-011-1772-6.
   PubMed Web of Science ®Google Scholar
• Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176(1):85–97. doi:10.2353/ajpath.2010.090517.
   PubMed Web of Science ®Google Scholar
• Reich B, Schmidbauer K, Rodriguez Gomez M, et al. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 2013;84(1):78–89. doi:10.1038/ki.2013.84.
   PubMed Web of Science ®Google Scholar
• Meng XM, Wang S, Huang XR, et al. Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. Cell Death Dis. 2016;7(12):e2495–e2495. doi:10.1038/cddis.2016.402.
   PubMedGoogle Scholar
• Wang S, Meng XM, Ng YY, et al. TGF-β/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosis. Oncotarget. 2016;7(8):8809–8822. doi:10.18632/oncotarget.6604.
   PubMedGoogle Scholar
• Wei J, Xu Z, Yan X. The role of the macrophage-to-myofibroblast transition in renal fibrosis. Front Immunol. 2022;13:934377. doi:10.3389/fimmu.2022.934377.
   PubMed Web of Science ®Google Scholar
• Chen J, Tang Y, Zhong Y, et al. P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition. Mol Ther. 2022;30(9):3017–3033. doi:10.1016/j.ymthe.2022.06.019.
   PubMed Web of Science ®Google Scholar
• Feng Y, Guo F, Xia Z, et al. Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition. Front Immunol. 2020;11:566535. doi:10.3389/fimmu.2020.566535.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu Q, Song J, et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of ­inflammatory cytokines in patients with rheumatoid arthritis. Mediators Inflamm.2015;2015:356040. doi:10.1155/2015/356040.
   PubMed Web of Science ®Google Scholar
• Kang Y, Yan Q, Fu Q, et al. Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis Res Ther. 2020;22(1):65. doi:10.1186/s13075-020-02154-7.
   PubMed Web of Science ®Google Scholar
• Hu G, Yu YF, Yin S, et al. Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren’s syndrome: a meta-analysis and trial sequential analysis. Eur Rev Med Pharmacol Sci. 2023;27:7544–7556. doi:10.26355/eurrev_202308_33406.
   PubMed Web of Science ®Google Scholar
• Long Z, Deng Y, He Q, et al. Efficacy and safety of iguratimod in the treatment of ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023;14:993860. doi:10.3389/fimmu.2023.993860.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Bian W, et al. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. Clin Rheumatol. 2020;39(2):491–497. doi:10.1007/s10067-019-04880-z.
   PubMed Web of Science ®Google Scholar
• Yan Q, Liu B, Wang J, et al. Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer. Front Med . 2023;10:1113408. doi:10.3389/fmed.2023.1113408.
   Web of Science ®Google Scholar
• Younis M, Wu Y, Fang Q, et al. Synergistic therapeutic antitumor effect of PD-1 blockade cellular vesicles in combination with iguratimod and rhodium nanoparticles. J Colloid Interface Sci. 2023;649:929–942. doi:10.1016/j.jcis.2023.06.030.
   PubMed Web of Science ®Google Scholar
• Shu P, Shao SQ, Cai XN, et al. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients. Eur Rev Med Pharmacol Sci. 2021;25:4687–4692. doi:10.26355/eurrev_202107_26379.
   PubMed Web of Science ®Google Scholar
• Shen L, Yin H, Sun L, et al. Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression. Arthritis Res Ther. 2023;25(1):151. doi:10.1186/s13075-023-03135-2.
   PubMed Web of Science ®Google Scholar
• Liu W, Han X, Li Q, et al. Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation. Biomed Pharmacother. 2022;153:113460. doi:10.1016/j.biopha.2022.113460.
   PubMed Web of Science ®Google Scholar
• Xue L, Xu J, Lu W, et al. Iguratimod alleviates tubulo-interstitial injury in mice with lupus. Ren Fail. 2022;44(1):636–647. doi:10.1080/0886022X.2022.2058962.
   PubMed Web of Science ®Google Scholar
• Xia Y, Fang X, Dai X, et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus. Int Immunopharmacol. 2021;96:107563. doi:10.1016/j.intimp.2021.107563.
   PubMed Web of Science ®Google Scholar
• Yan Q, Du F, Huang X, et al. Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLOS One. 2014;9(10):e108273. doi:10.1371/journal.pone.0108273.
   PubMed Web of Science ®Google Scholar
• Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1145–1152. doi:10.1038/ki.2009.86.
   PubMed Web of Science ®Google Scholar
• Radford MG, Jr., Donadio JV, Jr., Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8(2):199–207. doi:10.1681/ASN.V82199.
   PubMed Web of Science ®Google Scholar
• Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16(9):2702–2713. doi:10.1681/ASN.2005040435.
   PubMed Web of Science ®Google Scholar
• Toda G, Yamauchi T, Kadowaki T, et al. Preparation and culture of bone marrow-derived macrophages from mice for functional analysis. STAR Protoc. 2021;2(1):100246. doi:10.1016/j.xpro.2020.100246.
   PubMedGoogle Scholar
• Li X, Xu M, Shen J, et al. Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression. Cell Death Discov. 2022;8(1):281. doi:10.1038/s41420-022-01073-7.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou C, Xia W, et al. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma. Nat Commun. 2024;15(1):1009. doi:10.1038/s41467-024-45215-0.
   PubMed Web of Science ®Google Scholar
• Lyu T, Jiang H, Zeng L, et al. Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling. Arthritis Res Ther. 2023;25(1):152. doi:10.1186/s13075-023-03109-4.
   PubMed Web of Science ®Google Scholar
• Tang PM, Zhou S, Li CJ, et al. The proto-oncogene tyrosine protein kinase Src is essential for macrophage-myofibroblast transition during renal scarring. Kidney Int. 2018;93(1):173–187. doi:10.1016/j.kint.2017.07.026.
   PubMed Web of Science ®Google Scholar
• Guo Y, Mei F, Huang Y, et al. Matrix stiffness modulates tip cell formation through the p-PXN-Rac1-Yap signaling axis. Bioact Mater. 2022;7:364–376. doi:10.1016/j.bioactmat.2021.05.033.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Z, Yang X, et al. H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. Theranostics. 2021;11(3):1473–1492. doi:10.7150/thno.51245.
   PubMed Web of Science ®Google Scholar
• Hang Z, Wei J, Zheng M, et al. Iguratimod attenuates macrophage polarization and antibody-mediated rejection after renal transplant by regulating KLF4. Front Pharmacol. 2022;13:865363. doi:10.3389/fphar.2022.865363.
   PubMed Web of Science ®Google Scholar
• Tao J, Sun L, Wang Z, et al. Efficacy and safety of iguratimod supplement to the standard immunosuppressive regimen in highly mismatched renal transplant recipients: a pilot study. Front Immunol. 2021;12:738392. doi:10.3389/fimmu.2021.738392.
   PubMed Web of Science ®Google Scholar
• Chen RX, Cao SS, Zhao LD, et al. Obstructive uropathy associated with rheumatoid arthritis successfully treated with steroids and immunosuppressive therapy: a case report. Medicine . 2019;98(50):e18415. doi:10.1097/MD.0000000000018415.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gao H, Wang Q, et al. Molecular mechanisms and clinical application of iguratimod: a review. Biomed Pharmacother. 2020;122:109704. doi:10.1016/j.biopha.2019.109704.
   PubMed Web of Science ®Google Scholar
• Shao S, Qu Z, Liang Y, et al. Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-α in mice. Int Immunopharmacol. 2021;99:107936. doi:10.1016/j.intimp.2021.107936.
   PubMed Web of Science ®Google Scholar
• Xie X, Gan H, Tian J, et al. Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis. Eur J Clin Invest. 2022;52(8):e13791. doi:10.1111/eci.13791.
   PubMed Web of Science ®Google Scholar
• Li G, Yamasaki R, Fang M, et al. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic ­experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep. 2018;8(1):1933. doi:10.1038/s41598-018-20390-5.
   PubMedGoogle Scholar
• Gan K, Yang L, Xu L, et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Int Immunopharmacol. 2016;35:294–300. doi:10.1016/j.intimp.2016.03.038.
   PubMed Web of Science ®Google Scholar
• Fu C, Jiang L, Hao S, et al. Activation of the IL-4/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells. Front Immunol. 2019;10:2638. doi:10.3389/fimmu.2019.02638.
   PubMed Web of Science ®Google Scholar
• Rahal OM, Wolfe AR, Mandal PK, et al. Blocking interleukin (IL)4- and IL13-Mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2018;100(4):1034–1043. doi:10.1016/j.ijrobp.2017.11.043.
   PubMed Web of Science ®Google Scholar
• Liang H, Zhang Z, Yan J, et al. The IL-4 receptor α has a critical role in bone marrow-derived fibroblast activation and renal fibrosis. Kidney Int. 2017;92(6):1433–1443. doi:10.1016/j.kint.2017.04.021.
   PubMed Web of Science ®Google Scholar
• Lin H, Wu C, Zhu F, et al. Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition. Adv Med Sci. 2020;65(2):338–347. doi:10.1016/j.advms.2020.05.006.
   PubMed Web of Science ®Google Scholar
• Yan Y, Ma L, Zhou X, et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 2016;89(1):68–81. doi:10.1038/ki.2015.293.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang H, Han C, et al. Src promotes anti-inflammatory (M2) macrophage generation via the IL-4/STAT6 pathway. Cytokine. 2018;111:209–215. doi:10.1016/j.cyto.2018.08.030.
   PubMed Web of Science ®Google Scholar